Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 4

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Breast 2

Conditions

Muscular Atrophy 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × ostarine × Clear all
NCT05065411 2024-02-26

VERU-024

Veru Inc.

Phase 3 Terminated
5 enrolled
Breast

Breast Neoplasms

NCT04869943 2024-01-26

ARTEST

Veru Inc.

Phase 3 Terminated
52 enrolled
Breast

Breast Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT01355497 2020-11-09

Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

GTx

Phase 3 Completed
330 enrolled 7 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Muscular Atrophy

NCT01355484 2016-03-03

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

GTx

Phase 3 Completed
321 enrolled 7 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Muscular Atrophy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡